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INTRODUCTION 
 
 
Spinal analgesia was first performed by August Bier   on 16th august  
1898 when he injected 3ml of 0.5% cocaine intrathecally.  Spinal 
anaesthesia is simple, easy to perform and has got a definite endpoint for 
successful positioning of needle. The spinal analgesia is rapid in onset and 
the spread of analgesic can be controlled. It requires a small dose of local 
anaesthetic yet produces profound sensory and motor blockade. 
Ever since the introduction of local anaesthetics, diverse classes of 
drugs such as epinephrine, opioids, clonidine, neostigmine, ketamine and 
benzodiazepines have been added as adjuvants to local anaesthetics in an 
attempt to prolong analgesia and reduce the incidence of side effects. 
Magnesium has been called “Nature’s physiological calcium channel 
Blocker”.  Parenteral magnesium has been used for many years on an 
empirical basis for intraoperative and postoperative analgesia. 
Although systemic magnesium decreases postoperative opioid 
requirements, its intrathecal use has not been evaluated clinically. However, 
it has been safely used in humans and its safety profile has been documented 
by histopathological analysis in experimental studies. 
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In 1906, Haubold and Meltzer showed that intrathecal 
administration of magnesium sulphate produces spinal anaesthesia that 
includes profound motor and sensory blockade without any permanent 
untoward effects. 
In this prospective randomized double blind controlled study, we 
evaluated the effect of adding intrathecal magnesium sulphate to 
bupivacaine and fentanyl in patients undergoing elective lower abdominal 
surgeries. 
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AIM OF THE STUDY 
 
To evaluate the effect of intrathecal magnesium sulphate as an adjunct 
to bupivacaine – fentanyl  in patients undergoing  elective lower abdominal 
surgeries. 
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SPINAL ANAESTHESIA 
             Spinal (subarachnoid/intrathecal) anaesthesia is a form of central 
neuraxial   block in which a temporary interruption of nerve transmission is 
achieved following injection of local anesthetic and/or adjuvant solutions 
into the subarachnoid space. Spinal anaesthesia is the most frequently 
employed methods of regional anesthesia. 
 
ANATOMY: 
             The vertebral canal extends from the foramen magnum to the sacral 
hiatus.  It is formed by the dorsal spine, pedicles and lamina of successive 
vertebrae (7 cervical, 12 thoracic, 5 lumbar and 5 sacral). The vertebrae are 
held together by a series of overlapping ligaments namely the anterior and 
posterior longitudinal ligaments, ligamentum flavum, interspinous ligament, 
supraspinous ligament and the intervertebral discs. 
            The spinal cord, a direct continuation of the medulla oblongata 
begins at the upper border of the atlas and terminates distally in the conus 
medullaris.  The distal termination, because of the differential growth rates 
between the bony vertebral canal and central nervous system varies from L3 
in the infant, to the lower border of L1or upper border of L2 in the adult. 
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             Surrounding the spinal cord in the bony vertebral column are three 
membranes (from within to the periphery), the piamater, arachnoidmater and 
duramater. The piamater is a highly vascular membrane that closely invests 
the spinal cord.  The arachnoidmater is a delicate neovascular membrane 
closely attached to the outermost duramater.  Between the two innermost 
membranes is the subarachnoid space. In this space are the cerebrospinal 
fluid, spinal nerves, blood vessels that supply the spinal cord and the 
denticulate ligaments. Although the spinal cord ends at the lower border of 
L1 in adults, the subarachnoid space continues to S2.  
The outermost membrane in the spinal canal is the longitudinally 
organized fibroelastic membrane, the duramater.  This layer is the direct 
extension of the cranial duramater and extends as the spinal duramater from 
the foramen magnum to S2, where the filum terminale (an extension of the 
piamater beginning at the conus medullaris) blends with the periosteum of 
the subdural space which contains only small amounts of serous fluids to 
allow the duramater and arachnoidmater move over each other.   
Surrounding the duramater is the epidural space which extends from 
the foramen magnum to the sacral hiatus.  Posterior to the epidural space is 
the ligamentum flavum which extends from the foramen magnum to the 
sacral hiatus. Ligamentum flavum extends from the anterior inferior aspect 
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of the lamina above to the posterior superior aspect of the lamina below.  
Immediately posterior to the ligamentum flavum is the interspinous 
ligament.  Extending from the external occipital protuberance to the coccyx, 
posterior to these structures is the supraspinous ligament. 
  Lumbar puncture is routinely done below the L2 vertebrae down to 
the L5-S1 interspace to avoid damaging the spinal cord which ends at the 
lower border of L1 in adults. 
 
PHYSIOLOGY OF SUBARACHNOID BLOCK: 
Cerebrospinal Fluid: 
           The cerebrospinal fluid (CSF) is an ultrafiltrate of blood plasma with 
which it is in hydrostatic and osmotic equilibrium.  It is a clear, colorless 
fluid found in the spinal and cranial subarachnoid space and in the ventricles 
of the brain.  The average volume in the adult ranges from 120-150 ml of 
which 35 ml is in the ventricles, 25 ml is in the cerebral subarachnoid space 
and 75 ml is in the spinal subarachnoid space.  It is secreted by the choroid 
plexus at a rate of 0.3-0.4 ml/minute. 
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Physical Characteristics of Cerebrospinal Fluid: 
pH           7.4 
Specific gravity (H2O): 
At body temperature 
At 4 degree centigrade 
 
       1.007 
        1.0003 
Density     1.0003 g/ml 
Baricity        1.000 
Pressure 8-12 mm Hg/70-80 mm H2O 
Cells       3-5/cu.mm 
Proteins          20 mg/dl 
Glucose     45-80 mg/dl 
       
         The cerebrospinal fluid plays an important role in spinal anesthesia as a 
media for dispersion of the local anesthetic drug to the spinal nerve.  An 
important factor determining the spread of drugs in the subarachnoid space 
is the specific gravity of the injected solution compared with that of CSF. 
 
Mechanism of Spinal Anaesthesia: 
        Injection of local anesthetic solution into the spinal CSF allows access 
to sites of action both within the spinal cord and the peripheral nerve roots.  
The nerve roots leaving the spinal canal are not covered by epithelium and 
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are readily exposed to the local anesthetic within the CSF. Therefore afferent 
impulses leaving via the ventral nerve roots are blocked during spinal 
anesthesia. Local anesthetics block sodium channels and electrical 
conduction in spinal nerve roots.  There are also multiple potential actions of 
local anesthetics within the spinal cord at different sites.  Local anaesthetics 
can exert sodium channel block within the dorsal and ventral horns, 
inhibiting generation and propagation of electrical activity.   
 
Zone of Differential Blockade: 
 Sensory: 
       In Subarachnoid block, sympathetic fibres are two to three segments 
higher than sensory fibres. Sympathetic block will be greater when more 
concentrated solutions are used or when adrenaline is added, as this has a 
similar effect. 
Motor:  
         In Subarachnoid block, the difference between sensory and motor block 
is slight (Two segments). 
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Order of blocking nerve fibers: 
1. Autonomic preganglionic β fibers. 
2. Temperature fibers- Cold before warm. 
3. Pinprick fibers. 
4. Fibers conveying pain greater than pin prick. 
5. Touch fibers. 
6. Deep pressure fibers. 
7. Somatic motor fibers. 
8. Fibers conveying vibratory sense and proprioceptic impulses. 
        During recovery, return of sensibility in the reverse order was 
assumed, but it has been suggested that sympathetic activity returns 
before sensation. 
 
Spread of Local Anaesthetics in subarachnoid space: 
           Local anesthetic solution is diluted by CSF and therefore its original 
concentration is of less amount than the actual mass of drug injected.  
Spread is also determined by the baricity of the injected solution.  Baricity is 
a ratio comparing the density of a local anesthetic solution at a specified 
temperature to the density of CSF at the same temperature.  A hypobaric 
solution has a baricity less than 1.0000 or specific gravity less than 
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1.0069(the mean value of specific gravity).  A hyperbaric solution has a 
baricity greater than 1.0000 or specific gravity more than 1.0069.  Hypobaric 
and Hyperbaric solutions are prepared from isobaric solutions by the 
addition of various amounts of sterile distilled water and dextrose 
respectively.  Isobaric solutions do not move under the influence of gravity 
in the CSF.  Hyperbaric solutions, being heavier than CSF, settle to the most 
dependent aspect of the subarachnoid space, which is determined by the 
position of the patient.  In supine patient, hyperbaric solutions gravitate to 
the thoracic kyphosis.  Hypobaric solution floats up to the nerves innervating 
the surgical site. The major factors affecting height of the block are the 
baricity of the local anesthetic solution and the dosage of drug injected. 
 
Fate of Local Anaesthetics in Subarachnoid Space: 
             Following injection of local anaesthetic solution into subarachnoid 
space, its concentration falls rapidly.  The initial steep fall is due to mixing 
with CSF and subsequent absorption into nerve roots and spinal cord.  The 
egress of local anesthetic solution following subarachnoid injection is 
primarily by vascular absorption with no hydrolysis or degradation taking 
place in the CSF.  Depending on the type of the drug used, it is metabolized 
in plasma by pseudocholinesterase or in the liver. 
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 Indications for subarachnoid block:    
          Spinal anesthesia can be administered whenever a surgical procedure 
can be done with a sensory level of anesthesia that does not produce adverse 
patient outcome which includes 
• Lower abdominal surgeries 
• Lower limb surgeries 
• Urological procedures 
• Obstetric procedures 
• Gynecological surgeries 
• Perineal and rectal surgeries 
Contraindications for subarachnoid block:    
                        An absolute contraindication for subarachnoid block is 
patient refusal. 
        Other contraindications are: 
• Local sepsis 
• Uncorrected coagulopathy 
• Uncontrolled blood loss/shock 
• Fixed cardiac output states 
• Documented allergy to local anesthetics 
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• Raised intracranial pressure 
• Neurological disease 
• Major spine deformities/previous surgery on the spine 
• Severe cardiac disease 
Factors Influencing height of analgesia in Subarachnoid Block:  
• Dose of the drug injected 
• Volume of fluid injected 
• Specific gravity of the solution 
• Position of the patient during injection 
• Posture of patient after injection 
• Choice of interspace 
• Patient factors- Age, Height, Pregnancy, Spinal stenosis 
Factors not influencing height of analgesia in Subarachnoid 
Block: 
• Patient factors- Weight, Sex 
• Barbotage 
• Speed of injection 
• Composition and circulation of cerebrospinal fluid 
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• Direction of bevel of the standard needle (although not of the 
Whitacre needle) 
Complications of subarachnoid block: 
Immediate: 
• Hypotension 
• Bradycardia 
• Toxicity due to intravascular injection 
• Allergic reaction to local Anesthetic 
• Hypoventilation (brain stem hypoxia) 
Delayed: 
• Post dural puncture headache 
• Retention of urine 
• Backache 
• Meningitis 
• Transient lesions of cauda equine 
• Sixth nerve palsy 
• Anterior spinal artery syndrome 
• Horner’s syndrome 
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Circulatory effects of subarachnoid block: 
There are six different ways in which subarachnoid block can influence 
the cardiovascular system. 
1. Vasodilatation of resistance and capacitance vessels. 
2. Block of cardiac efferent sympathetic fibres from T1 to T4 resulting 
in loss of chronotropic and inotropic drive and fall in cardiac output. 
3. The atrial or Bainbridge reflex causing bradycardia. 
4. The operation of Marey’s law causing tachycardia. 
5. Depression of vascular smooth muscle and β-adrenergic blockade of 
myocardium with fall in cardiac output, following systemic 
absorption of the local anesthetic drug. 
6. Adrenaline effect (if used), following absorption, resulting in β 
stimulation and associated rise in cardiac output and reduction in 
peripheral resistance. The overall effect is likely to be a greater fall in 
mean arterial pressure than if adrenaline had not been used. 
 
Theories of causation of fall in Blood pressure: 
1. Diminished cardiac output consequent on reduction of venous return 
and lack of muscular propulsive forces on veins. 
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2. Dilatation of post arteriolar capillaries and small venules due to 
paralysis of vasoconstrictors. 
3. Paralysis of Sympathetic nerve supply to the heart (T1-T4). 
Bradycardia may give rise to fall in cardiac output. 
4. Paralysis of Sympathetic nerve supply to adrenal glands (Splanchnic 
nerves), with consequent catecholamine depletion. 
5. Absorption of drug into circulation. 
6. Ischaemia and hypoxia of vital centres. 
7. Hypovolemia, if present, may give rise to severe fall in blood pressure 
if central neuraxial blockade is employed. 
8. Compression of great vessels within the abdomen by the pregnant 
uterus, abdominal tumors or abdominal packs may cause severe 
hypotension in the presence of central neural blockade.  
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PHARMACOLOGY OF BUPIVACAINE 
 
BUPIVACAINE 
 
 
It is an amide local anaesthetic characterized as pipecoloxylidides.Addition 
of a butyl group to the piperidine nitrogen of mepivacaine results in 
Bupivacaine. It is a chiral drug because of possession of asymmetric carbon 
atom. 
It was first synthesized in Sweden by Ekenstam and his colleagues in 1957 
and used clinically by L.J.Telivuo in 1963. Its molecular weight is 288. 
MECHANISM OF ACTION  
It prevents transmission of nerve impulses by inhibiting passage of 
sodium ions through ion selective sodium channels in nerve membranes. 
They do not alter the resting transmembrane potential or threshold potential. 
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PHARMACOKINETICS 
It is a weak base that has pk value above physiologic pH.  At pH 7.4 
only 15% exists in nonionised form. Absorption depends on the site of 
injection, dosage and use of epinephrine. Lung is capable of extracting 
bupivacaine from circulation, which will limit concentration of drug that 
reaches systemic circulation. This first pass pulmonary extraction is dose 
dependent suggesting that it becomes saturated rapidly. 
 
 Pk      :          8.1 
Protein Binding     :          95% 
Lipid solubility    :          28 
Volume of distribution   :          73 litre 
Clearance of drug from plasma  :          0.471 lit/min 
Elimination half life   :          210 min   (3.5 hours) 
Onset time : 5 -7 min 
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METABOLISM  
  Slowest metabolism among amide local anaesthetics. It undergoes 
aromatic hydroxylation, N- dealkylation, amide hydrolysis and conjugation. 
Only the N-desbutyl bupivacaine has been measured in blood or urine after 
epidural or spinal anaesthesia. Alpha-1 acid glycoprotein is the most 
important protein-binding site of bupivacaine. 
 
SIDE EFFECTS 
Bupivacaine is more cardio toxic than equieffective doses of   
lignocaine. This is manifested by severe ventricular arrhythmias and 
myocardial depression. Bupivacaine blocks cardiac Na+ channels rapidly 
during systole and dissociates more slowly during diastole, so that a 
significant fraction of Na+ channels remain blocked at the end of the 
diastole. Thus the block by Bupivacaine is cumulative and substantially 
greater. 
CLINICAL USE 
Onset of anaesthesia and duration of action are long. Its tendency to 
provide more sensory than motor block has made it popular for providing 
postoperative analgesia. Used mainly for 
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o Infiltration anaesthesia    
o Field block anaesthesia 
o Nerve block anaesthesia 
o Spinal anaesthesia 
o Epidural anaesthesia 
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PHARMACOLOGY OF FENTANYL 
 
Fentanyl is a synthetic phenylpiperidine opioid of the 4-anilopiperidine 
series which is structurally related to pethidine. 
Commercially, fentanyl is formulated as a citrate, available as an 
aqueous solution without preservatives. Each ml contains a base of 50mcg of 
fentanyl. 
 
PHYSICOCHEMICAL PROFILE 
 
        Molecular weight                                  528.29 
        pKa                                                        8.4 
        % unionized at pH 7.4                           8.5 % 
        Octanol / water partition coefficient      816 
        % bound to plasma proteins                   84 % 
        Potency                                                   80 times more 
potent than morphine 
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PHARMACODYNAMICS 
Analgesia 
  Analgesia results from action of fentanyl on opoid mu receptors both 
supraspinally in the brain and in the spinal cord. Intravenous fentanyl 
produces effective analgesia at plasma concentrations between  
0.6 - 3.0 ng/ml. 
 
Cardiovascular system 
Arterial blood pressure, cardiac output and pulmonary vascular 
resistance remain unchanged after large doses of intravenous fentanyl.  
Fentanyl like other opioid  agonists (except pethidine ) causes bradycardia, 
that responds to intravenous atropine. Peripheral vasodilation is much less 
than morphine due to absence of histamine Release. 
 
Respiratory System 
Fentanyl causes a direct dose related respiratory depression by its 
depressant effect on the medullary respiratory centre, manifested as a 
decreased sensitivity to Carbondioxide and reduced respiratory rate. It is 
reversed by intravenous Naloxone administration. Plasma fentanyl 
concentrations >2ng/ml is associated with clinical respiratory depression. 
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The degree of respiratory depression is affected by various factors, including 
type of surgery, age and individual pharmacodynamic response. 
 
Central nervous system 
Fentanyl causes less sedation than equianalgesic doses of morphine . 
In doses of 10 mcg/kg , fentanyl causes dose related reduction in cerebral 
blood flow and CMRO2.  Muscle rigidity probably reflects a manifestation 
of a catatonic state, a basic pharmacological property of opioids, related to 
enhancement of dopamine biosynthesis in the caudate nucleus. 
 
Gastrointestinal Tract 
Fentanyl decreases gastrointestinal tract motility, increases intrabiliary 
pressure and causes a varying incidence of nausea and vomiting.  The 
vomiting is mediated via stimulation of the chemoreceptor trigger zone in 
the area postrema. 
 
Genito-urinary system 
Fentanyl like other opioids causes relaxation of the detrusor muscle 
and increase in the urethral sphincter tone leading to urinary retention. This 
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is probably not dose related and is more common with central neuraxial 
administration. 
 
Pharmacokinetics 
Fentanyl is a potent opioid, highly lipophilic, producing a rapid onset 
of action of relatively short duration. After intravenous administration, 
fentanyl is rapidly distributed to brain, heart and other highly perfused 
tissues. It also crosses the placental barrier easily.  Peak effect occurs in 5 
minutes. Within a short time, the drug redistributes to the inactive tissues 
sites like skeletal muscle and fat, associated with decrease in plasma 
concentration of drug, thus terminating its effect.  About 75% of initial dose 
undergoes first pass pulmonary uptake. When low doses(1-2mcg/kg) are 
administered, redistribution terminates the effect and the drug appears short 
acting. With administration of large intravenous doses or continous infusion, 
progressive saturation of inactive tissue sites occur.  
 
Pharmacokinetic Profile 
Volume of distribution at steady state(VDss)            335litres 
Clearance                                                                   1530 ml/min 
Effect- site equilibration time                                    6.8 min  
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Hepatic extraction ratio                                              0.8-0.1 
Context – sensitive half time (4 hrs infusion)             260 mins 
Elimination half time                                                  3.1 to 6.6 hours 
 
Metabolism 
Fentanyl is biotransformed in the liver to inactive metabolites, 
primarily Norfentanyl and several hydroxylation products. Only 4-7% of 
drug is excreted unchanged in the urine. Elimination half time of fentanyl is 
longer than that of morphine because of the high lipid solubility of fentanyl.  
Eliminition half time is prolonged in elderly Patients.  A high hepatic 
extraction ratio means that the clearance of fentanyl is limited by hepatic 
blood flow. 
 
ROUTES OF ADMINISTRATION AND DOSAGE 
 Intramuscular 
50-100mcg may be administrated as premedication 30-60 minutes 
prior to surgery. 
Intravenous 
 Can be given intraoperatively and postoperative analgesia. Postoperative 
analgesia is achieved by intravenous loading dose of 1-2mcg/kg followed by 
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a Continous / variable infusion at rate of 1-2 mcg/kg/hr.  It can be used for 
Patient-Controlled analgesia (PCA) as a bolus dose of 20-50mcg with 
lockout intervals. 
 
Transdermal 
Transdermal fentanyl patch is available in four sizes, providing 
sustained release of fentanyl  at rates of 25, 50, 75 and 100mcg/hr for 
periods of 48-72 hours. Skin acts as a secondary reservoir contributing to 
prolonged residual fentanyl concentrations. 
 
Transmucosal 
Oral transmucosal fentanyl citrate (OTFC) incorporates fentanyl 
citrate in a candy mixture shaped into a lozenges or stick. The median time 
to onset of analgesia is 4 minutes and the duration of analgesia lasts for 
about 150 minutes. 
 
Intranasal 
Fentanyl is administered with a metered dose device, with each spray 
delivering 4.5mcg fentanyl. Time to onset of analgesia is about 15 minutes. 
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Transpulmonary 
  Inhalational administration of fentanyl produces rapid, effective drug 
delivery. A dose of 300mcg of fentanyl administered via oxygen driven 
nebuliser produces effective postoperative analgesia in 5 mins and lasts for 
about 2 hours. 
 
Neuraxial administration 
Epidural and intrathecal administration of fentanyl are long  stablished 
routes for intraoperative and postoperative analgesia. Epidural dose as a 
single bolus administration varies from 1-3 mcg/kg. Analgesia begins in 15 
minutes lasting for 2-4 hours.  Epidural infusion rates range from 0.5-
2.5mcg/kg/h.  In addition, fentanyl has been used in Patient controlled 
epidural Analgesia(PCEA) in doses of 20-25mcg with a lockout interval of 
6-10mins and background infusion in the rate  0.5-1mcg/kg/h.The minimum 
intrathecal bolus requirement for postoperative analgesia is 20mcg while a 
dose of 10mcg is effective in obstetric patients. Onset of analgesia is usually 
within 5-15 mins and duration is variable, ranging from 1-5 hours. Other 
modes of administration include continous / bolus administration via an 
intrathecal Catheter. 
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Clinical Applications 
Premedication 
Fentanyl in doses of 50- 100mcg may be administered intramuscularly 
30-60 minutes prior to surgery. Oral transmucosal fentanyl citrate in doses 
between 15-20mcg/kg, administered 45 minutes before surgery produces 
reliable preoperative sedation and facilitates induction of anaesthesia in 
children. 
 
Adjunct to general anaesthesia. 
Fentanyl in doses of 1-2mcg/kg given intravenously provides 
analgesia. It can be used as an adjuvant to blunt circulatory responses that 
occur during direct laryngoscopy for endotracheal intubation and sudden 
changes in the level of surgical stimulation . Large doses of fentanyl, 50-
150mcg/kg intravenously has been used  especially in cardiothoracic 
procedures, principally because of  its stable hemodynamic effects. 
 
Neurolept analgesia 
Innovar is a premixed combination containing 2.5 mg Droperidol and 
0.05mg Fentanyl in each ml (50:1) used for neurolept analgesia and 
anaesthesia. 
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Adjunct in central neuraxial block 
Fentanyl added to local anaesthetic either intrathecally or epidurally, 
improves the quality of intraoperative analgesia and also provides good post 
operative Analgesia. 
 
Postoperative analgesia 
Fentanyl administration by intravenous, epidural, intrathecal and 
transdermal routes provides effective postoperative analgesia. Newer routes 
like intranasal and inhalational administration are being evaluated as less 
invasive means of postoperative analgesia. 
 
Side effects 
Commonly occurring side effects include dose dependant respiratory 
depression, muscle rigidity, nausea and vomiting, pruritus, urinary retention 
and bradycardia. These effects are reversed by administration of naloxone 
intravenously. 
 
Intrathecal fentanyl 
Intrathecal fentanyl administration is an established route for 
intraoperative and postoperative analgesia. 
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Pharmacokinetics 
Fentanyl has the same baricity as cerebrospinal fluid at room 
temperature and addition to hyperbaric lignocaine or bupivacaine makes the 
solution hyperbaric. On injection into subarachnoid space, fentanyl mixes 
with csf and attaches itself to spinal opioid receptors. Protein binding of drug 
in the CSF is negligible and the concentration of opioid in the csf is thus free 
drug concentration.  CSF dynamics donot provide any means of drug 
removal. Diffusion into the spinal cord and absorption into the blood 
flowing through spinal cord must remove all the fentanyl. This rate 
determining step of drug removal is likely to be the rate constant for fentanyl 
transfer from csf to spinal cord and this rate constant is directly related to 
lipophilicity.  Fentanyl can also migrate from the csf into epidural vascular 
compartment via the duramater. However details of systemic 
pharmacokinetics of fentanyl are not known. Once in the csf, fentanyl like 
other opioids, spreads rostrally. Because of the high affinity of fentanyl with 
binding sites in the lipid-rich Spinal cord, only 10% of administered dose 
migrates to cervical region. 
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Application 
Intrathecal fentanyl is usually combined with local anaesthetics for 
perioperative anaesthesia and analgesia particularly in obstetrics. Fentanyl 
administration intrathecally provides more intense and complete analgesia at 
rest, at a lower dose requirement when compared to the epidural or 
intravenous routes. 
Modes of administration and dosages 
Fentanyl is administered intrathecally as single bolus injection or as 
repeated observer-administered, PCA boluses and continous infusion via an 
intrathecal catheter. Effective postoperative analgesia can be achieved with 
bolus doses of 20mcg.  Infusions of 0.8mcg/kg/h produces satisfactory 
analgesia in patients undergoing thoracotomy. 
Side effects of intrathecal fentanyl  
Side effects are relatively minor with intrathecal fentanyl. The 
incidence of clinically significant respiratory depression is relatively low, as 
Intrathecal administration of fentanyl results in lower systemic absorption 
than epidural route and the intrathecal dose requirement. A 30% incidence of 
urinary retention, varying incidence of pruritus and occasional episodes of 
nausea have been observed 
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PHARMACOLOGY OF MAGNESIUM 
 
It is a bivalent ion like calcium with an atomic weight of 24.312. 
Human body contains 1 mole (24g) of magnesium. It is the fourth common 
mineral salt in the body after phosporus, calcium and potassium, second 
intracellular cation after potassium. In serum, magnesium is divided into 
three fractions- 
1) Ionised, 
2) Protein bound and 
3) Contained in anion complexes.  
These fractions account for 65%, 27%, and 8% in serum concentration 
respectively. 
 
CHEMICAL STRUCTURE OF MAGNISIUM SULPHATE: 
 
Magnesium sulphate 
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PROPERTIES OF MAGNESIUM SULPHATE: 
1) CELLULAR PROPERTIES: 
Magnesium intervenes in the activation of membrane calcium ATPase 
and Na+ K+ ATPase involved in transmembrane ion exchange during 
depolarization and repolarization phases. It acts as a stabilizer of cell 
membrane and intracytoplasmic organelles. 
2) ION CHANNELS: 
It acts as a regulator of different ion channels. It has a competitive 
antagonist action against calcium inflows thereby limiting the outflow of 
calcium from the sarcoplasmic reticulum. So it is a calcium channel blocker 
and calcium channel modulator. 
3) CARDIOVASCULAR SYSTEM: 
It acts on calcium channels in the myocardial muscle and also acts 
indirectly on the cardiac muscle by inhibiting the calcium uptake on the 
Troponin C of the myocytes and thereby influencing myocardial 
contractility. 
Its vasodilatory action is due to its activation of cyclic AMP. This causes 
reduction in systolic blood pressure. 
Pulmonary vascular resistance is unaltered. 
Coronary vascular resistance is reduced and causes vasodilation. 
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4) NEUROMUSCULAR TRANSMISSION: 
It has a preponderant presynaptic and postsynaptic effect. Magnesium 
acts competitively in blocking the entry of calcium into the presynaptic 
endings. Presynaptic release of acetylcholine is reduced by magnesium, 
thereby decreasing the effect of acetylcholine on the postsynaptic receptors, 
which in turn increases the threshold of axonal excitation. 
It also produces progressive inhibition of catecholamine release from the 
adrenal medulla, adrenergic nerve endings and adrenergic postganglionic 
sympathetic fibers. 
 5) RESPIRATORY SYSTEM: 
It has bronchodilatory action due to the inhibition of smooth muscle 
contraction, histamine release from the mast cells and acetylcholine release 
from the cholinergic nerve endings. 
6) It is involved in hundreds of enzyme reactions in the body. 
7) Acts as a antagonist of NMDA receptors and this explains its use in  
Post-operative analgesia.  
8) Magnesium sulphate increases production of prostaglandins causing 
vasodilatation of the small intracranial vessels which is responsible for its 
anticonvulsant action. 
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CLINICAL USES: 
1) For Severe Preeclampsia and Eclampsia: 
A loading dose of 4-6gm magnesium sulphate diluted in 100ml of 
normal saline given over 15min intravenously. Then 2 gm/hr in 100ml of 
IV infusion. (maintain serum levels between 4 and 7mEq/L). 
Intermittent injection: 
 4gm given slow IV followed by 10gm, 5gm in each buttocks as deep 
IM injection. Then every 4hrs 5gm intramuscularly upto 24hrs after 
delivery. 
2) Magnesium sulphate has a tocolytic effect at serum levels of 8-10mEq/L. 
Loading dose of 4-6gm over 20min intravenously, then after the 
contraction ceases maintenance is done using 2-4gm per hour 
intravenously for 12-24 hours. 
3) To reduce the stress response during intubation, magnesium sulphate is 
used in the dosage of 30-50mg/kg. intravenously. 
4) In surgery for Phaeochromocytoma it helps to maintain haemodynamic 
balance because it inhibits the catecholamine release from adrenal 
medulla and adrenergic nerve endings. 
5) Nephritic Seizures: In children with nephritic seizures, the 50% 
concentration should be diluted to a 20% solution for i.m. injection. The 
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dose for children is 20 to 40 mg (0.1 to 0.2 mL of a 20% solution)/kg of 
body weight, administered i.m. as needed, to control seizures. 
6) It is used postoperatively in patients who have undergone Coronary 
artery bypass grafting to reduce the incidence of ventricular arrhythmias. 
7) It is also used in the treatment of Torsades De Pointes, as intravenously 
or intraosseously in the dosage of 25 to 50 mg/ kg (upto 2 gm). 
8) Acute myocardial infarction:  magnesium sulphate is used in the dose of 
2gm intravenously over 5-15 min followed by 18 gm over 24hrs as 
infusion. 
9) Total Parenteral Nutrition: In total parenteral nutrition, maintenance 
requirements for magnesium are not precisely known. The maintenance 
dose recommended for adults is 5 to 8 mEq magnesium/L of TPN 
solution; typical daily adult intake ranges from 10 to 24 mEq. For infants, 
the recommended intake ranges from 0.25 to 0.6 mEq/kg/day. 
10) In barium poisoning: 1-2gm is used to counteract the intense muscle 
stimulating effects of barium. 
11) In refractory bronchial asthma it is used for its bronchodilatory action. 
12) Hypomagnesemia: in case of mild deficiency 1gm every 6 hours for 4 
doses, in severe cases 1-5gms (2 – 10ml of 50% solution) in divided 
doses, repeated until the serum levels are normal. 
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13) Recent studies show its use in Tetanus patients, at a serum 
concentration of 2-4mEq/L, it gives good control of spasms and muscle 
rigidity. 
14) Magnesium sulphate is used in the dose of 50 mg intrathecally for 
potentiation of opioid analgesia. 
 
PRECAUTIONS: 
Because magnesium is removed from the body solely by the kidneys, 
the drug should be used with caution in patients with renal impairment. 
Urine output should be maintained at a level of 25 - 50 ml per hour. 
Monitoring serum magnesium levels and the patient's clinical status is 
essential to avoid the consequences of over dosage in toxemia. Clinical 
indications of a safe dosage regimen include the presence of the patellar 
reflex (knee jerk) and absence of respiratory depression (approximately 16 
breaths or more/minute). Serum magnesium levels usually sufficient to 
control convulsions range from 3 to 6 mg/100 ml (2.5 to 5.0 mEq/L). The 
strength of the deep tendon reflexes begins to diminish when magnesium 
levels exceed 4 mEq/L. Reflexes may be absent at 10 mEq magnesium/L, 
where respiratory paralysis is a potential hazard. An injectable calcium salt 
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should be immediately available to counteract the potential hazards of 
magnesium intoxication in eclampsia.  
Parenteral drug products should be inspected visually for particulate 
matter and discoloration prior to administration, whenever solution and 
container permit. Do not administer unless solution is clear and container is 
undamaged. Discard unused portion. 
 
PREPARATIONS AVAILABLE: 
Parenteral injection: Magnesium sulphate-    10%, 12.5%, 50% 
For Intravenous use only-                             4%, 8%. 
Magnesium sulphate in dextrose:                 1% in 5%dextrose. 
                                                                      2%in 5% dextrose. 
 
When administered intravenously the onset of action is immediate and 
duration of action is 30 min. on administration by intramuscular route the 
onset of action takes 1hr and duration of action is 3-4 hrs. 
Storage: 15-30degree centigrade. For IV use concentration of 20% or 
less should be used. Rate of injection should be 1.5ml/hr. 
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DRUG INTERACTIONS: 
Central nervous system depressants: When barbiturates, opiates, 
general anaesthetics, or other CNS depressants are administered 
concomitantly with magnesium sulfate, dosage of these agents must be 
carefully adjusted because of the additive central depressant effects.  
 
Neuromuscular blocking agents: Excessive neuromuscular blockade 
has occurred in patients receiving parenteral magnesium sulfate and a 
neuromuscular blocking agent; these drugs should be administered 
concomitantly only with caution. 
Cardiac glycosides: Magnesium salts should be administered with 
extreme caution in digitalized patients, because serious changes in cardiac 
conduction, which can result in heart block may occur if administration of 
calcium is required to treat magnesium toxicity. 
 
ADVERSE REACTIONS: 
The adverse effects of parenterally administered magnesium usually 
are the result of magnesium intoxication. These include flushing, sweating, 
hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory 
collapse, cardiac and CNS depression proceeding to respiratory paralysis. 
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Hypocalcemia with signs of tetany secondary to magnesium sulphate 
therapy for eclampsia, has been reported.  
 
SYMPTOMS AND TREATMENT OF OVERDOSE:  
Magnesium intoxication is manifested by a sharp drop in blood 
pressure and respiratory paralysis. Disappearance of the patellar reflex is a 
useful clinical sign to detect the onset of magnesium intoxication. In the 
event of overdosage, artificial ventilation must be provided until a calcium 
salt can be injected i.v. to antagonize the effects of magnesium.  
In adults, i.v. administration of 5 to 10 mEq of 10% calcium gluconate 
will usually reverse respiratory depression or heart block due to magnesium 
intoxication. In extreme cases, peritoneal dialysis or hemodialysis may be 
required 
Hypermagnesemia in the newborn may require resuscitation and 
assisted ventilation via endotracheal intubation or intermittent positive 
pressure ventilation, as well as i.v. calcium. 
 
 
 
 40
MATERIALS AND METHODS 
 
After approval of the study by our institutional ethics committee, the 
study was conducted in 50 ASA grade I or II patients undergoing elective 
lower abdominal surgeries   under spinal anaesthesia. The age of the patients 
ranged from 23– 68 years weighing 35 – 65 kg and height ranging from 150 
– 168 cms. All patients were thoroughly examined preoperatively.  
Informed written consent was obtained and the procedure was explained. For 
all patients age, weight, heights were noted.  
In the assessment room, vital parameters like pulse rate, blood 
pressure and baseline investigations like hemoglobin, urine analysis for 
albumin and sugar, blood sugar, urea and creatinine and ECG were checked. 
Thorough examination of all the systems and airway assessment was done.  
Exclusion criteria included significant co existing disease, long term 
opioid use, any contraindications to regional anaesthesia such as local 
infection or bleeding disorders. Visual Analog Scale (VAS) was explained to 
the patients. The patients were shown a 10 cm long scale marked 0 – 10 on a 
blank paper and told that 0 represented “no pain” and 10 represented worst 
possible pain. 
The patients were randomly allocated into two groups of 25 each. 
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GROUP S  
Patients received 2 ml 0.5% bupivacaine (10 mg) 
0.5 ml fentanyl (25 mcg)                                                                                        
1 ml normal saline 
GROUP M  
Patients received 2 ml 0.5% bupivacaine (10 mg) 
   0.5 ml fentanyl (25 mcg)  
 1 ml MgSO4 (50 mg) 
The total volume of the injected solution was 3.5 ml in both groups. In the 
operating room, appropriate equipment for airway management and 
emergency drugs were kept ready. Patients were shifted to the operating 
room. The horizontal position of the operating table was checked and the 
patients were positioned. Noninvasive blood pressure monitor, pulse 
oximeter and ECG leads were connected to the patient. Preoperative baseline  
systolic and diastolic blood pressure, pulse rate and oxygen saturation were 
recorded. Patients were cannulated with 18 G intravenous cannula and 
preloaded with 1000 ml of ringer lactate. The patient was placed in right 
lateral position. The skin over the back was prepared with antiseptic solution  
and draped with sterile towel. Lumbar puncture was performed with a 25G 
Quincke babcock spinal needle at L2 – L3 or L3 – L4 interspace via midline  
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approach. After confirming free flow of CSF, the prepared solution was 
injected.The patients were made to lie supine immediately after injection and 
the time at which the spinal anaesthesia performed was noted.  
The following parameters were observed: 
 
SENSORY BLOCK  
The onset of sensory block was defined as the time between the 
injection of anaesthetic solution and the absence of pain at the T10 
dermatome. Sensory block was assessed by loss of sensation to pinprick 
using 21G sterile needles bilaterally along the mid clavicular line. This 
assessment started immediately after turning the patient supine and 
continued every minute till loss of sensation to pinprick at T 10 level was 
noted. This pinpricking continued till the peak block height was reached and 
the time was noted. The duration of sensory block was defined as the time 
for regression of two segments from the maximum block height evaluated by 
pin prick. Sensory block was checked every 15 mins till it reached two 
segment regression levels. 
 
 
 
 43
MOTOR BLOCK  
Motor block was assessed bilaterally using Modified bromage scale. 
MODIFIED BROMAGE SCALE. 
0 - No block. Able to raise extended legs against gravity. 
 1 - Unable to raise extended leg, but just able to flex knees. 
2 - Unable to flex knees but able to flex ankle. 
 3 - Total block. Inability to flex ankle / move leg. 
 
Assessment of motor block was started immediately after turning the 
patient supine and continued every minute till bromage score of 1 was 
reached. The onset of motor block was defined as the time to achieve 
bromage score of 1 from the time of injection. Duration for complete motor 
block recovery was taken as the time from subarachnoid injection to return 
of bromage score of 0. 
 
VITAL SIGNS AND SIDE EFFECTS 
Systolic and diastolic blood pressure, pulse rate and oxygen saturation 
were recorded every 2 mins for the first 10 mins and thereafter every 5 mins 
until the immediate postoperative period. Hypotension was defined as fall in 
systolic blood pressure more than 30 % from baseline or systolic blood 
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pressure less than 90 mm Hg. This was managed with intravenous ephedrine 
in incremental dose of 6 mg.  
Bradycardia was defined as heart rate less than 60 / min and was 
planned to be managed with intravenous atropine in incremental doses. 
Respiratory depression was said to be present if respiratory rate was less 
than 8 per minute and / or SpO
2
 than 85 %.  This was planned to be managed 
with mask ventilation or intubation and IPPV.  Vomiting was planned to be 
managed with Inj. Odansetron 8 mg intravenously. Pruritis was planned to 
be managed with reassurance or  inj. Pheniramine maleate 22.75 mg 
intravenously. Urinary retention was monitored postoperatively and 
catheterization was planned in patients with retention more than 6 hours. 
Patients were shifted to post anaesthesia care unit after completion of 
surgery. Vital signs were recorded every 15 mins in the first hour after 
surgery, 30 mins for the next 2 hours and thereafter every hour for the next 3  
hours. Motor block was assessed till bromage score of 0 was reached. 
Patients were shifted to postoperative ward after complete resolution of 
motor blockade and stabilization of blood pressure.pain assessment was 
done using VAS every 15 mins till VAS score of 4 was reached. The VAS 
was also noted whenever the patient complained of pain. Inj.Diclofenac 
sodium 75 mg was given intramuscularly as the rescue analgesic when VAS   
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of 4 or more was reached. Patients were monitored for 24 hours to detect 
side effects like respiratory depression, urinary retention, pruritis, nausea 
and vomiting. 
 
DURATION OF ANALGESIA 
The time at which the patient first complained of pain was noted. The 
duration of effective analgesia was defined as the period from the spinal 
injection to the first occasion when the patient complained of pain in the 
postoperative period. 
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OBSERVATION AND ANALYSIS 
Of the fifty patients, 25 belonged to group S and other 25 belonged to 
 group M. 
 
AGE DISTRIBUTION 
The age distribution in group S was 24 to 65 years while in group M 
was 23 to 68 years. The mean age and age distribution in both groups were  
Statistically similar (p value 0.949) which is as under 
 
 
AGE IN YEARS 
 
GROUP S 
 
GROUP M 
 
MINIMUM 
 
24 
 
23 
 
MAXIMUM 
 
65 
 
68 
 
MEAN 
 
41.36 
 
41.92 
 
 
 
SEX DISTRIBUTION 
Of the 50 pts, 27 were male and 23 were female. The distribution was 
similar in both the groups as shown by the table and bar diagram. 
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SEX 
 
GROUP S 
 
GROUP M 
 
MALE 
 
14 
 
13 
 
FEMALE 
 
11 
 
12 
 
TOTAL 
 
25 
 
25 
 
 
 
WEIGHT DISTRIBUTION 
 
The mean weight of the patients in both the groups were comparable  
(p value 0.616). 
 
 
WEIGHT IN KG 
 
GROUP S 
 
GROUP M 
 
Range 
 
35 - 64 
 
35 - 65 
 
Mean 
 
47.96 
 
47.28 
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HEIGHT DISTRIBUTION 
The mean height was also statistically comparable in both the groups  
( p value 0.837). 
 
 
HEIGHT IN CM 
 
GROUP S 
 
GROUP M 
 
Range 
 
150 - 164 
 
150 - 168 
 
Mean 
 
155.76 
 
155.32 
 
 
 
SENSORY BLOCKADE 
 
 
 
SENSORY 
BLOCKADE 
( IN MINS ) 
 
GROUP S 
 
GROUP M 
 
P VALUE 
 
ONSET 
 
4.28 ± 0.98 
 
4.48 ± 0.96 
 
0.470 
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MOTOR BLOCKADE 
 
 
MOTOR 
BLOCKADE 
(IN MINS ) 
 
GROUP S 
 
GROUP M 
 
P VALUE 
 
ONSET 
 
5.08 ± 0.86 
 
5.24 ± 0.78 
 
0.494 
 
TIME FOR 
COMPLETE 
MOTOR 
RECOVERY 
 
130.36 ±  10.4 
 
131.4 ± 10.5 
 
0.936 
 
 
 
DURATION OF ANALGESIA 
 The  mean duration of effective analgesia was 141.48 ± 11 mins with 
a range of 120 – 161 mins in group S but in group M it was 154.56 ± 11.1 
mins with a range of 133 – 174 mins.  The probability value, as detected by 
two sample students “t” test is 0.083. 
 
 
 
 
GROUP S 
 
GROUP M 
 
P VALUE 
 
DURATION OF 
ANALGESIA 
(IN MINS ) 
 
141.48 ± 11 
 
154.56 ± 11.1 
 
0.083 
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SIDE EFFECTS 
 
GROUP S 
 
GROUP M 
NAUSEA AND VOMITING 4 3 
SHIVERING 3 3 
PRURITIS 5 6 
URINARY RETENTION 3 4 
BRADYCARDIA - - 
RESPIRATORY DEPRESSION - - 
HYPOTENSION 12 13 
 
MEAN ± S.D 
PARAMETERS GROUP S GROUP M P VALUE 
 
 
AGE 41.36 ±  12.9 41.92 ±  13.4 0.949 
 
 
HEIGHT 155.76 ±  4.68 155.32 ±  4.89 0.837 
 
 
WEIGHT 47.96  ± 10.5 47.28  ± 7.79 0.616 
ONSET OF SENSORY BLOCK 
 
4.28 ± 0.98 
 
4.48 ± 0.96 
 
0.470 
ONSET OF MOTOR BLOCK 
 
5.08 ± 0.86 
 
5.24 ± 0.78 
 
0.494 
DURATION FOR COMPLETE 
MOTOR RECOVERY 
 
130.36 ±  10.4 
 
131.4 ± 10.5 
 
0.936 
DURATION OF ANALGESIA 
 
141.48 ± 11 
 
154.56 ± 11.1 
 
0.083 
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REVIEW OF LITERATURE 
 
M.OZALEVLI et al had done a study about the effect of adding 
intrathecal magnesium sulphate to bupivacaine and fentanyl in patients 
undergoing lower extremity surgeries. Group S, the saline group received 2 
ml 0.5% bupivacaine ( 10 mg ) 0.5 ml  fentanyl ( 25 mcg) and 1 ml  normal 
saline intrathecally. Group M  received  2 ml 0.5% bupivacaine ( 10 mg ) 0.5 
ml  fentanyl (  25 mcg)  and 1 ml  MgSO4 ( 50 mg ) intrathecally. The total 
volume of the injected solution was 3.5 ml in both groups .The onset of 
sensory blockade was delayed in Group M (12 mins in group s vs 17 mins in 
group m ). The duration of sensory block was similar in both groups (  85 
mins in both groups ).The onset of motor blockade was delayed in group M  
( 16 mins in group S vs 20 mins in group M ).The study explained the 
probable reason for the delay in onset that the solution to which  magnesium  
sulphate was added had a different pH. The duration of spinal analgesia was 
longer in group M (155 mins in group S vs 173 mins in group M). The 
mechanism they cited was magnesium  sulphate , as an NMDA antagonist 
has prevented central sensitization due to peripheral nociceptive 
stimulation.The incidence of side effects were similar in both the groups.The 
study concluded that magnesium  sulphate when added intrathecally to 
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bupivacaine and  fentanyl delayed  the onset of both  sensory and motor 
blockade but prolonged the period of analgesia without increasing the 
incidence of side effects.                                                                                                              
 
BUVENDRAN et al conducted a study evaluating whether intrathecal 
magnesium could prolong spinal opioid (fentanyl) analgesia in patients 
requiring labour analgesia. Patiets were allocated into two groups. Group F  
received  0.5 ml  fentanyl (25 mcg)  and 3 ml  normal saline whereas Group 
F+ M   received  0.5 ml  fentanyl (25 mcg)  and 3 ml  magnesium sulphate  
(50 mg) . The duration of spinal analgesia was longer in Group F+ M       (75 
mins) compared with group F (60 mins).  There were no differences in the 
demographic characteristics, hemodynamic parameters and foetal heart rate. 
 
KROIN et al demonstrated that magnesium sulphate potentiates 
morphine analgesia when administered intrathecally in normal rats and 
suggested that intrathecal magnesium sulphate may be a useful adjuvant to 
spinal morphine analgesia. Histological evaluation of the spinal cord showed 
identical histologic changes with the control group and the animals had no 
neurological deficit. They demonstrated that intrathecal magnesium sulphate 
has a safety profile. 
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SIMPSON et al  studied intrathecal magnesium sulphate effect in 
dogs undergoing thoracic aortic cross clamping via small thoracotomy 
incision and  concluded that intrathecal magnesium sulphate can prevent 
spinal cord injury. None of the histological specimens from dogs that 
received magnesium exhibited any histologic evidence of ischaemic and 
neurological injury. This study also demonstrates the safety profile of 
intrathecal magnesium sulphate. 
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DISCUSSION 
The primary aim of this study was to evaluate the effect of adding 
magnesium sulphate to bupivacaine and fentanyl spinal anaesthesia. The 
safety of intrathecal magnesium sulphate administration in humans and 
animals have been established. SIMPSON et al and KROIN et al 
demonstrated  in animals that intrathecal magnesium sulphate has a safety 
profile. Histological evaluation of the spinal cord showed identical 
histologic changes with the control group and the animals had no 
neurological deficit. M.OZALEVLI et al and BUVENDRAN et al 
demonstrated no deleterious effects in humans on administration of 
intrathecal magnesium sulphate. 
 The dose of magnesium sulphate used in this study was based on data 
from M.OZALEVLI et al and BUVENDRAN et al where 50 mg of 
magnesium sulphate potentiated opioid analgesia. The dose of magnesium 
sulphate was based on data from a rat model of postoperative pain in which 
188 micrograms of intrathecal magnesium sulphate potentiated morphine 
antinociception done by KROIN et al. Based on the relative differences 
between human and rat CSF volume and body weight, the 188 microgram 
dose was conservatively extrapolated to 50 mg for humans. 
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SENSORY AND MOTOR BLOCKADE 
The time to onset of  motor blockade was 5.08 ± 0.86 mins in group S  
and  5.24 ± 0.78 mins  in  group M ( p value 0.494)which means that both 
the groups showed  no statistical difference in onset. 
The time to achieve complete recovery of motor blockade was130.36 
± 10.4 mins in group S  and was 131.4 ± 10.5 mins  in group M (p value 
0.936) which shows that the duration of motor blockade was similar in both 
the groups.  
The mean time to sensory onset at T 10 was 4.28 ± 0.98 mins in group 
S and 4.48 ± 0.96mins in group M (p value 0.470).  This implies that the 
onset of sensory block was similar in both the groups. 
 
DURATION OF EFFECTIVE ANALGESIA 
 The  mean duration of effective analgesia was 141.48 ± 11 mins with 
a range of 120 – 161 mins in group S but in group M it was 154.56 ± 11.1 
mins with a range of 133 – 174 mins.  The probability value  as detected by 
two sample students “t” test  is 0.083. This implies that addition of  
intrathecal magnesium sulphate to bupivacaine and  fentanyl prolonged the 
period of analgesia but the potentiation was not statistically significant in our 
study. 
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This correlates with the study done by M.OZALEVLI et al who 
concluded that addition of intrathecal magnesium sulphate to bupivacaine 
and  fentanyl  prolonged the period of analgesia. 
 This also correlates with the study done by BUVENDRAN et al who 
concluded that magnesium sulphate when administered intrathecally 
prolonged the duration of spinal opioid analgesia in humans. 
  
SIDE EFFECTS 
The incidence of nausea and vomiting was 16 % in group S and 12% in 
group M. The incidence of shivering was similar in both the groups (12 %) 
The incidence of pruritis was 16 % in group S and 12% in group M. The 
incidence of urinary retention was 16 % in group S and 12% in group M. 
Hypotension occurred in 48% of the patients in group S and 52% of the 
patients in group M. 
 From the above findings it is clear that the incidence of side effects 
were similar in both the groups. 
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SUMMARY 
We conducted a double blinded randomized controlled study in 50 
patients belonging to ASA I and II undergoing elective lower abdominal 
surgeries  to evaluate the effect of adding intrathecal magnesium sulphate to 
bupivacaine and fentanyl. For the same reason , we divided randomly the 
patients into two groups of 25 each. 
Group S received  2 ml 0.5% bupivacaine (10 mg) ,0.5 ml  fentanyl 
(25 mcg)  and  1 ml  normal saline .                                                                                           
Group M received  2 ml 0.5% bupivacaine (10 mg) ,0.5 ml  fentanyl 
(25 mcg) and 1 ml  MgSO4 (50 mg). 
The total volume of the injected solution was 3.5 ml in both groups. 
The onset of sensory and motor blockade, the duration of sensory and motor 
blockade and the duration of analgesia were noted in both the groups. 
Demographic data were similar in both the groups. 
We found that the onset of sensory and motor blockade was similar in 
both the groups . The duration of sensory and motor blockade was also 
similar in both the groups. 
 The duration of analgesia was  prolonged in the magnesium sulphate 
group but the potentiation was not significant in our study. 
 The incidence of  side effects were similar in both the groups . 
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CONCLUSION 
This study concludes that intrathecal magnesium sulphate  when 
added to bupivacaine  and fentanyl prolonged the period of analgesia but not 
significantly in patients undergoing elective lower abdominal surgeries  
without increasing the incidence of  side effects. 
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PROFORMA  
THE EFFECT OF ADDING INTRATHECAL MAGNESIUM SULPHATE 
TO BUPIVACAINE – FENTANYL SPINAL ANAESTHESIA  IN PATIENTS 
UNDERGOING  LOWER ABDOMINAL SURGERIES 
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POSTOPERATIVE MONITORING 
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Patient in forward flexion; Tuffier's line is shown. 
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